Editorial
The use of everolimus in pediatric kidney transplantation
First published: 07 May 2014
No abstract is available for this article.
References
- 1Ferraresso M, Belingheri M, Ginevri F, et al. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients. Pediatr Transplant 2014: 18: 350–356.
- 2Cibrik D, Silva HT, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013: 95: 933–942.
- 3Pape L, Offner G, Kreuzer M, et al. De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010: 10: 2349–2354.
- 4Pape L, Lehner F, Blume C, Ahlenstiel T. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 2011: 92: 658–662.
- 5Ganschow R, Pape L, Sturm E, et al. Growing experience with mTOR inhibitors in pediatric solid organ transplantation. Pediatr Transplant 2013: 17: 694–706.
- 6Grushkin C, Mahan JD, Mange KC, Hexham JM, Ettenger R; for the Everolimus Pediatric Study Group. De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: A prospective, multicenter, 12-month study. Pediatr Transplant 2013: 17: 237–243.
- 7Kanzelmeyer NK, Ahlenstiel T, Drube J, et al. Protocol biopsy-driven interventions after pediatric renal transplantation. Pediatr Transplant 2010: 14: 1012–1018.
- 8Ettenger R, Hoyer PF, Grimm P, et al. Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year. Pediatr Transplant 2008: 12: 456–463.
- 9Tönshoff B, Pape L, Ettenger R,et al. Early conversion of calcineurin inhibitor to everolimus in de novo paediatric renal transplant recipients and its impact on efficacy and renal function; design of an open-label, randomised, multi-centre study. 24th International Congress of the Transplantation Society, July 15–19, 2012 THU.PO39.035.
- 10Kranz B, Wingen AM, Vester U, König J, Hoyer PF. Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation. Pediatr Nephrol 2013: 28: 1293–1298.
- 11Billing H, Burmeister G, Plotnicki L, et al. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients. Transpl Int 2013: 26: 903–909.
